Clinical trials: No Reflow
No Reflow Phenomenon, STEMI
No Reflow Phenomenon Incidence and Predictors
Background No reflow phenomenon is described in up to 65% of patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI).
- Trial name
- NORM-PPCI (NCT04017169)
- Testing
- No intervention as observational study
- Where
- United Kingdom
- Volunteers
- 176 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Acute Myocardial Infarction, Persisting Ischemia
Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia
Patients presenting with large myocardial infarction and signs of persistent ischemia after successful percutaneous coronary intervention, have a poor prognosis with respect to outcome and development of heart failure in the…
- Conditions
- Acute Myocardial Infarction, Persisting Ischemia, No Reflow
- Trial name
- SEMPER FI (NCT02125526)
- Testing
- Intra-aortic balloon pump
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Lokien van Nunen
Myocardial Infarction, Percutaneous Coronary Intervention
Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
The purpose of this study is to determine whether intracoronary selective thrombolysis are more effective than tirofiban on the coronary flow during primary percutaneous coronary intervention for the acute myocardial infarction.
- Conditions
- Myocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy
- Trial name
- ERUPTION (NCT02131220)
- Testing
- Prourokinase, Tirofiban, normal saline
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Fudan University
Reperfusion Injury, Myocardial
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
This study is a single-center, prospective controlled trial addressing effectiveness of empagliflozin on cardiac-renal injury in patients with STEMI.
- Trial name
- NCT03591991
- Testing
- Empagliflozin
- Volunteers
- 128 people
- Sponsor
- Chinese PLA General Hospital
No-Reflow Phenomenon, STEMI - ST Elevation Myocardial Infarction
NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction
The aim of this study is to investigate the association between NGAL plasma levels in ST-elevation myocardial infarction and the no-reflow phenomenon, adverse events during hospitalization and at 30-day follow-up.
- Trial name
- NCT03264859
- Testing
- NGAL levels early and post STEMI
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Dipeptidyl-peptidase-4, STEMI
Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding
Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI).
- Conditions
- Dipeptidyl-peptidase-4, STEMI, PCI, No-reflow
- Trial name
- NCT02849691
- Volunteers
- 747 people
- Sponsor
- Chinese PLA General Hospital
Coronary Artery Disease, Coronary Artery Ectasia
Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method
This study evaluates the effects of emotional status on coronary flow in patients undergoing elective coronary angiography. Patients whom undergoing elective coronary angiography will fulfill the Beck Anxiety Inventory, Beck…
- Conditions
- Coronary Artery Disease, Coronary Artery Ectasia, Slow-Flow Phenomenon, Endothelial Dysfunction
- Trial name
- STRAIN-TIMI (NCT02831153)
- Testing
- coronary angiography
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Ertan YETKIN
Coronary Angiography, Coronary Artery Disease
Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)
The aim of this study is to evaluate and describe the total coronary circulation time (TCCT) by using TIMI frame count method in patients performed coronary angiography.
- Conditions
- Coronary Angiography, Coronary Artery Disease, Coronary Artery Ectasia, Slow-Flow Phenomenon
- Trial name
- TCCT-TIMI (NCT02818127)
- Testing
- coronary angiography
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 2,000 people
- Sponsor
- Vascular and Molecular Cardiology Society
Percutaneous Coronary Intervention, No-reflow Phenomen
The RESTORE-SIRIO Randomized Controlled Trial
Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy for treating acute ST-segment elevation myocardial infarction (STEMI).
- Conditions
- Percutaneous Coronary Intervention, No-reflow Phenomen, Acute ST-segment Elevation Myocardial Infarction
- Trial name
- RESTORE-SIRIO (NCT02405130)
- Testing
- intracoronary epinephrine, no intracoronary epinephrine
- Where
- Germany
- Sponsor
- Heinrich-Heine University, Duesseldorf
Coronary Arteriosclerosis, Coronary Heart Disease
Analysis of Human Coronary Aspirate
During elective percutaneous coronary intervention (PCI), both proximal and distal protection devices are used. The distal occlusion protection device temporarily occludes the vessel distal to the lesion during the intervention…
- Conditions
- Coronary Arteriosclerosis, Coronary Heart Disease, No Reflow Phenomenon
- Trial name
- AHCA (NCT01430884)
- Testing
- Aspirated Coronary Blood
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Universität Duisburg-Essen
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
No-Reflow Phenomenon
Intracoronary Tirofiban on No-Reflow Phenomena
The goal of this study was to evaluate the acute effect of intracoronary administration of tirofiban on no-reflow phenomenon in patients with STEMI and occurrence of no-reflow phenomenon undergoing primary percutaneous coronary…
- Trial name
- NCT02054000
- Testing
- Tirofiban
- Where
- Turkey (Türkiye)
- Volunteers
- 162 people
- Sponsor
- TC Erciyes University
Acute Myocardial Infarction, Percutaneous Coronary Intervention
Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction
The purpose of this study is to evaluate the efficacy of three different vasodilators including diltiazem, verapamil and nitroglycerin for reversal of no-reflow/slow-flow during direct percutaneous coronary intervention for acute…
- Trial name
- EDUCATE-AMI (NCT00712894)
- Testing
- Diltiazem, Verapamil, Nitroglycerin
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Fudan University